UNSPSC 51381910: Parecoxib sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H17N2O4S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EB87433V6F, chemically known as propanamide, n-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)-, sodium salt but more generally known as parecoxib sodium, which bears US NIH Compound Identifier 9576744. European Medicines Agency schedules Parecoxib sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12548MIG.

UNSPSC 51381910 Parecoxib sodium is a Commodity code that in current state and local procurement practice covers pharmaceutical products procured through competitive bidding and cooperative purchasing vehicles, though recent activity under this specific code shows limited direct alignment with parecoxib itself. State and local governments, counties, and health agencies are instead sourcing naloxone, over-the-counter pharmaceuticals, generic multi-source drugs, and other pharmaceutical products through this taxonomy entry. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of multiple jurisdictions and member agencies. The work encompasses product specification by National Drug Code, compliance with FDA and cGMP requirements, contract pricing through multiple wholesaler channels, and quarterly or ongoing supply delivery.

Recent opportunities show activity across Florida and the upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due by July 26, 2023, requiring unit-cost bids with shipping included and a two-year initial term plus one-year renewal option. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) in January 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor information on direct-to-manufacturer prescription programs for a Therapeutic Pharmacy Initiative, signaling upstream state-level interest in reshaping pharmacy supply relationships. Cooperative purchasing vehicles are significant in this space, as demonstrated by MMCAP's multistate reach.